Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds

Patent metadata

Field	Value
Publication number	US-9303021-B2
Application number	US-201414218501-A
Country	US
Kind code	B2
Filing date	Mar 18, 2014
Priority date	Mar 6, 2007
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas 1 and 2

wherein the variables have the meaning disclosed in the specification.

First claim

What is claimed is:

1. A method for treating a cognitive disorder, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the following structure:

or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, wherein:
X is O or S;
R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 5 or 6 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups or cyano groups with one or two alkyl groups having 1 to 6 carbons,
R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, aryl or heteroaryl, aryl-alkyl, aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroaryl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, and
the wavy lines represent bonds connected to carbons having R or S configuration,

with the proviso that the claim does not cover the compound shown below

and wherein the cognitive disorder is associated with a neurodegenerative disease selected from the group consisting of Alzheimer's disease, corticobasal degeneration, Creutzfeldt-Jacob disease, frontotemporal lobar degeneration, Huntington disease, multiple sclerosis, normal pressure hydrocephalus, organic chronic brain syndrome, Parkinson's disease, Pick disease, progressive supranuclear palsy, and senile dementia (Alzheimer type).

2. The method of claim 1 , wherein the compound has the following structure:

or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

4. The method of claim 2 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

5. The method of claim 2 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

6. The method of claim 2 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound has the following structure

or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the compound is (2S,3S)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

9. The method of claim 7 , wherein the compound is (2S,3R)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

10. The method of claim 7 , wherein the compound is (2R,3S)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

11. The method of claim 7 , wherein the compound is (2R,3R)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one, or pharmaceutically acceptable salt thereof.

Assignees

• Allergan Inc

Inventors

• Donello John E
• Schweighoffer Fabien J
• Luhrs Lauren M

Classifications

• C07D405/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D213/50

  Ketonic radicals · CPC title

• C07D295/192

  from aromatic carboxylic acids · CPC title

• C07D215/14

  Radicals substituted by oxygen atoms · CPC title

• C07D333/22

  Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom · CPC title